News

During the meeting with the FDA, male sexuality was mutually determined not to be appropriate as a clinical endpoint. As a result of the meeting, Repros plans to

Genentech has reported that third quarter US net sales for Tarceva were approximately $101 million, a 1% increase over the same quarter of the last year. OSI stated

JEGC retains a non-exclusive right to purchase the shares under the agreement, which remains in effect subject to both parties’ right to terminate the agreement. Earlier, TLC Vision

Innovive expects to begin enrollment in its pivotal Phase II study in the fourth quarter of 2007. Innovive has recently reached an agreement with the FDA on a

The all-natural medicine has been approved in China for external use to treat human papillomavirus and herpes simplex virus. Tests have shown an inhibitory effect on the growth

The drug, XP21510, is a non-hormonal, oral product for the potential treatment of women diagnosed with menorrhagia, or heavy menstrual bleeding. It is estimated that 9 to 14%

The payment arises from an agreement between the two companies and reflects progress in the development of bazedoxifene, a selective estrogen receptor modulator. Bazedoxifene is a synthetic drug

The approval is based on data from a prospective Phase I pharmacokinetic trial in patients with varying degrees of kidney impairments. The results of the study satisfy a

The analyses of Lialda’s 303 trial, a long-term, Phase III, open-label 12-14 month extension study, will be presented at the American College of Gastroenterology meeting in Philadelphia. A